About Exeltis
Exeltis is a Healthcare company based in Madrid (Spain) founded in 2003. Small molecule therapeutics are developed for various diseases. Exeltis has completed 1 acquisition, including Quinnova Pharmaceuticals. Its website exeltis.com draws about 30 thousand monthly visits. Exeltis offers products and services including Innovative Treatments and Nutritive Specialties. Its focus areas include Life Sciences, Pulmonology, Drugs and Diversified. Its legal entity is Exeltis Pharmaceuticals Holding, S.L.
Company details
Exeltis was founded in 2003 and is headquartered in Madrid, Spain. Therapeutics based on small molecules are developed by the company for conditions in areas such as respiratory health, endocrinology, dermatology, and womens health. The pipeline features products including Trifamox, indicated for upper and lower respiratory tract infections, and Eluzer, used in treating inoperable malignant pleural mesothelioma. Operations focus on pharmaceutical development within these sectors.
- Headquarters Madrid, Spain
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website exeltis.com
- Social LinkedIn X
- Legal Name Exeltis Pharmaceuticals Holding, S.L.
- Investments & Acquisitions
Products & Services of Exeltis
Exeltis offers a comprehensive portfolio of products and services, including Innovative Treatments and Nutritive Specialties.
Develops solutions for unmet medical needs
Provides nutritional products for health support
People of Exeltis
58 people are tracked at Exeltis (24 in leadership, 34 in team).
| Name | Role | Group |
|---|---|---|
Prashant Menon | Managing Director | Leadership |
Mathi Muthukamatchi | Plant Director | Leadership |
Wriddhee Maitra | Director, Human Resources & Administration | Leadership |
Lesley Werth | Director Of Clinical Operations | Leadership |
Bishal Roy | COO | Leadership |
Satish Joshi | CFO | Leadership |
Ketan Dhamanaskar | Managing Director | Leadership |
Cedric Charroin | Regional Head Nordics - Belux - Morocco | Leadership |
Lilián Blanhir Gutiérrez | Head Of Gynecology Marketing | Leadership |
Vanesa Gonzalez Zarza | Associate Director, Supply Chain, Planning And Business Analytics – Exeltis & Xiromed LLC | Leadership |
José Luis Rodríguez | Business Support Director | Leadership |
Wael Khattab | Medical Affairs Director Middle East & Africa | Leadership |
Sriram Krishnaswamy | General Manager -sfe India & Global Markets | Leadership |
Amy White | Director Of Commercial Operations | Leadership |
Lucy Oscós Gil | Business Unit Director | Leadership |
Filippo Favalli | Head Of Medical Affairs Italy | Leadership |
Sandra López Luis | Head Of Digital Marketing | Leadership |
Arturo Hurtado Olea | Head Of Finance Administration | Leadership |
Ahmed Saad | Head Of Operation | Leadership |
David Rodrigues | Director, Sales Operations | Leadership |
38 more people are available in the full profile.
Complete people profiles for Exeltis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Exeltis
Exeltis has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Quinnova Pharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
| quinnova.com | Newtown Square, United States | 2003 | Dec 2013 | •••• |
Complete acquisition details for Exeltis
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Exeltis
2 dated milestones of Exeltis across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Exeltis is founded.
- Acquisition Acquires Quinnova Pharmaceuticals.
Web traffic of Exeltis
The website of Exeltis (exeltis.com) receives about 29.6K visits a month and ranks #1,223,472 among all websites worldwide, #1,542 in Biotechnology and Pharmaceuticals.
- Monthly visits29.6K
▲ 22.7% vs previous month
- Unique visitors10.3K
per month
- Global rank#1,223,472
among all websites
- Category rank#1,542
Health · Biotechnology and Pharmaceuticals
- Bounce rate42%
- Pages per visit1.6
- Average visit27 sec
- DevicesDesktop 42% · Mobile 58%
Websites whose visitors overlap most with Exeltis. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
tucanaldesalud.com | tucanaldesalud.com | 100% | #202,257 | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Exeltis
Complete news archive for Exeltis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Exeltis
Exeltis was founded in 2003.
Exeltis is headquartered in Madrid, Spain. It is registered at Madrid, Madrid, Spain.
Exeltis was founded in 2003 and is headquartered in Madrid, Spain. Therapeutics based on small molecules are developed by the company for conditions in areas such as respiratory health, endocrinology, dermatology, and womens health. The pipeline features products including Trifamox, indicated for upper and lower respiratory tract infections, and Eluzer, used in treating inoperable malignant pleural mesothelioma. Operations focus on pharmaceutical development within these sectors.
Exeltis offers Innovative Treatments and Nutritive Specialties.
Exeltis has made 1 acquisition, including Quinnova Pharmaceuticals.
Exeltis operates through Exeltis Pharmaceuticals Holding, S.L..